PR Newswire·Aug 13, 2026, 4:15 PM ET

Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program

Aethlon Medical, Inc. reported fiscal first quarter results ended June 30, 2026, with cash and cash equivalents of approximately $4.9 million as of that date.
The company's Phase 1 oncology study in Australia dosed the first participant in the third \& final cohort, showing early signs of reduced tumor-derived extracellular vesicles \& improved immune function.
A manuscript regarding extracellular vesicle characteristics in Long COVID patients was accepted for publication in the International Journal of Molecular Sciences, demonstrating the Hemopurifier's binding capability to these vesicles.
Post-quarter financing raised approximately $4.0 million in gross proceeds through a public stock offering, with management projecting cash resources sufficient for 12 months of operations.
Consolidated operating expenses for the quarter decreased 11.9% to approximately $1.6 million, driven by lower professional fees \& reduced general, administrative, \& preclinical research costs.
The company will host a conference call today, August 13, 2026, at 4:30 p.m. ET to discuss financial results \& corporate updates, with a replay available until September 13, 2026.
The Hemopurifier holds FDA Breakthrough Device Designation for treating advanced cancer unresponsive to standard care \& life-threatening viruses not addressed by approved therapies.